Biofabricated tissue implants for soft tissue repair, wound healing, and trauma care.
Technological Advantage
Proprietary DLP-based bioprinting process; interdisciplinary expertise in tissue engineering; validated through zero-gravity R&D and animal trials.
Differentiation
Value Proposition
Enables the production of vascularized human tissues and organ models with high resolution, reducing the gap between lab-grown tissues and clinical implants.
How They Differentiate
Focus on high-resolution vascularization and scalable tissue therapeutics using tailor-made biomaterials.
Market & Competition
Target Customers
Regenerative medicine patients and researchers
Industry Verticals
Medical; Biotechnology; Regenerative Medicine
Competitors
Allevi, Regemat 3D, Cellink
Growth & Milestones
Growth Metrics
€10M raise in March 2026; Positive animal trials in April 2025; Team of 20-30 from 14 nations
Major Milestones
Founded in 2017; Earliest operations as Cellbricks GmbH in 2018; Received Bayer G4A and BMBF grants; Closed EUR 5M Seed II round; Established Boston expansion hub; Initiated in vivo studies for liver patches and breast implants; Zero-gravity bioprinting tests with BIH/Charité; Positive animal trials in April 2025; €10M funding round in March 2026
Notable Customers
Charité – Universitätsmedizin Berlin; Berlin Institute of Health (BIH); Robert Koch Institute (RKI); Bayer; TissUse GmbH; Technische Universität Berlin (TU Berlin); Max Delbrück Center for Molecular Medicine (MDC); Leibniz Institute of Polymer Research Dresden; Orthopaedic University Hospital Heidelberg
Cellbricks occupies a distinctive position in the bioprinting landscape by focusing on high-resolution vascularization of multi-cell-type tissues, a critical bottleneck in moving lab-grown constructs toward clinical implants. Unlike many bioprinting firms that emphasize cell-laden hydrogel extrusion, Cellbricks uses a proprietary DLP-based vat photopolymerization process to create complex, perfusable vascular networks within tissue grafts. This approach aims to solve the oxygen and nutrient diffusion limits that constrain the size and viability of engineered tissues.
The company's core technology is a light-based bioprinting platform that builds structures layer by layer using photocurable bioinks. By integrating multiple cell types and biomaterials in a single print, Cellbricks can produce constructs that more closely mimic native tissue architecture. Its product pipeline targets soft tissue repair, wound healing, and trauma care, with specific programs including liver patches and breast implants. The company has validated its process through zero-gravity experiments with Charité and the Berlin Institute of Health, as well as positive animal trials completed in April 2025.
Cellbricks serves researchers and clinicians in regenerative medicine, biotechnology, and medical device development. Its notable partners include Charité – Universitätsmedizin Berlin, the Robert Koch Institute, Bayer, TissUse GmbH, and several German research institutes. The company has raised approximately €10 million in total funding, including a €5 million Seed II round and a €10 million round closed in March 2026, with backing from Silicon Roundabout Ventures, SPRIND, ACT Venture Partners, and B.value. It operates from Berlin and a Boston expansion hub, with a team of 20-30 people from 14 nations.
The company's strategic moat rests on its proprietary DLP bioprinting process and interdisciplinary expertise in tissue engineering, supported by nine patent families covering high-resolution light-based bioprinting and specialized bioinks. However, it faces competition from established bioprinting hardware makers such as Allevi, Regemat 3D, and Cellink, which offer broader platforms for academic and pharmaceutical customers. Cellbricks' differentiation lies in its focus on scalable, vascularized tissue therapeutics rather than general-purpose bioprinting tools, but the path from animal trials to regulated clinical products remains long and capital-intensive.